Change in serum concentrations of PINP from baseline to week 24 in the evaluable population

<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> The median percentage change (95% CI) from baseline was consistently positive only for exemestane (24%; 95% CI, 11–30%). The overall differences between the four groups were not statistically significant (= 0.147 using the Kruskall–Wallis test). CI, confidence interval; PINP, procollagen type I N-terminal propeptide

Change in U-NTx concentrations from baseline to week 24 in the evaluable population

<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> UNTx, adjusted urinary N-terminal telopeptide of type I collagen

Baseline-adjusted AUCfor serum concentrations of PINP in the evaluable population

<p><b>Copyright information:</b></p><p>Taken from "Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women"</p><p>http://breast-cancer-research.com/content/9/4/R52</p><p>Breast cancer research : BCR 2007;9(4):R52-R52.</p><p>Published online 10 Aug 2007</p><p>PMCID:PMC2206728.</p><p></p> The increase in baseline-adjusted AUCfor exemestane was 187% (95% CI, 95–295%). The AUCfor exemestane was significantly greater than anastrozole (= 0.004), letrozole (< 0.001), or placebo (= 0.033). Changes in baseline-adjusted AUCwere not statistically significant for other active treatments or placebo. The overall differences between the four groups were statistically significant (= 0.004 using the Kruskall–Wallis test). AUC, area under the curve; PINP, procollagen type I N-terminal propeptide

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations